Munich, April 23, 2015 — Adiuvo Investment S.A. from Warsaw, Poland has closed an oversubscribed 23.8Mn PLN (app. 5.8Mn EUR) in a Pre-IPO financing round versus initial target of 3Mn EUR. CM-Equity is pleased to announce that we have successfully supported Adiuvo’s capital increase as placement agent.
Founded in 2014 by its CEO Marek Orlowski, Adiuvo is an investment holding company in mobile health, medical technologies and wellbeing. The Pre-IPO investment will finance market expansion of the current portfolio, further development of existing technologies (new products, new applications) and beginning of the collaboration with pipeline companies. All Target Companies hold secured worldwide IP for their technologies.
About Adiuvo S.A.: Adiuvo S.A. is an investment holding company registered in Warsaw, Poland. Adiuvo invests in mobile health, medical technologies and wellbeing companies and technologies sourced worldwide and co-developed in Poland. The company is having nine companies in portfolio, six advanced, three exploratory, four pipeline deals soft circled. Four of these companies invoice first revenues in Q1 2015, one company has distribution deal with a Global Player. Most of the investments have been leveraged by the Polish Government R&D Grants (non-dilutive financing) from various innovation support programs Access to non-dilutive financing provides up to 1:4 leverage of all R&D investment and allows Adiuvo to enter projects in an opportunistic way on almost every project stage.
Polish Government Grants Program: Government R&D grants can cover clinical data generation in health projects that don’t concern pharmaceutical compounds. In 2014 Adiuvo was selected by the National Centre for Research and Development (Polish government agency) as the winner of the Bridge VC competition. This entitles Adiuvo to receive 82,5 Mio PLN (20,1 Mio EUR) unsecured subordinated loans and non-returnable subsidies.